595 related articles for article (PubMed ID: 16581184)
1. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
2. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
3. A chemical neurotoxin, MPTP induces Parkinson's disease like phenotype, movement disorders and persistent loss of dopamine neurons in medaka fish.
Matsui H; Taniguchi Y; Inoue H; Uemura K; Takeda S; Takahashi R
Neurosci Res; 2009 Nov; 65(3):263-71. PubMed ID: 19665499
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
5. Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice.
Liu J; Wang MW; Gu P; Ma QY; Wang YY; Geng Y; Yuan ZY; Cui DS; Zhang ZX; Ma L; Zhang BH; Zhou MG; Zhu AP
Brain Res; 2010 Jul; 1345():213-20. PubMed ID: 20546706
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Teng X; Sakai T; Liu L; Sakai R; Kaji R; Fukui K
J Neurochem; 2006 May; 97(4):1126-35. PubMed ID: 16686692
[TBL] [Abstract][Full Text] [Related]
7. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
9. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
10. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P
Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823
[TBL] [Abstract][Full Text] [Related]
11. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication.
Rolland AS; Tandé D; Herrero MT; Luquin MR; Vazquez-Claverie M; Karachi C; Hirsch EC; François C
J Neurochem; 2009 Aug; 110(4):1321-9. PubMed ID: 19527435
[TBL] [Abstract][Full Text] [Related]
13. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
[TBL] [Abstract][Full Text] [Related]
14. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
15. Potential neuroprotective effect of low dose whole-body gamma-irradiation against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice.
Liang Y; Li S; Zou Q; Su B
Neurosci Lett; 2006 Jun; 400(3):213-7. PubMed ID: 16540245
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Goldberg NR; Haack AK; Lim NS; Janson OK; Meshul CK
Neuroscience; 2011 Apr; 180():256-71. PubMed ID: 21335067
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
18. A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: pharmacological validation with R-(-)-deprenyl.
Quinn LP; Perren MJ; Brackenborough KT; Woodhams PL; Vidgeon-Hart M; Chapman H; Pangalos MN; Upton N; Virley DJ
J Neurosci Methods; 2007 Aug; 164(1):43-9. PubMed ID: 17498809
[TBL] [Abstract][Full Text] [Related]
19. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease.
Chao YX; He BP; Tay SS
J Neuroimmunol; 2009 Nov; 216(1-2):39-50. PubMed ID: 19819031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
